Interim results of phase II clinical testing of gadobenate dimeglumine.
Rosati
G
G
Medical Department, R&D Division, Bracco S.p.A., Milan, Italy.
Pirovano
G
G
Spinazzi
A
A
D000328:Adult; D001927:Brain Diseases / Q000175:diagnosis; D003287:Contrast Media / Q000009:adverse effects; D006801:Humans; D008107:Liver Diseases / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D008536:Meglumine / Q000009:adverse effects / Q000031:analogs & derivatives*; D009203:Myocardial Infarction / Q000175:diagnosis; D009942:Organometallic Compounds / Q000009:adverse effects; D016037:Single-Blind Method
D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine